Journal: Current Drug Delivery
Guest editor(s): Saurabh Srivastava

Introduction

The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to neoplastic sites via interaction with cell surface primer sites. The integration of nanotechnology in drug delivery holds potential for optimizing the pharmacokinetics, therapeutic efficacy, and chemical stability of chemotherapeutic compounds. Consequently, a nuanced exploration of nanotechnology-driven chemotherapy, specifically tailored for Head and Neck cancer, is imperative to augment the scientific discourse and advance therapeutic interventions in this challenging clinical domain. This issue may contribute to the acquisition of advanced knowledge pertaining to Head and Neck, and associated cancers, thereby fostering a deeper understanding of the intricacies underlying these malignancies.

Keywords

drug delivery, chemotherapy, cancer, mouth cancer, oral cancer, nanotechnology, head & neck cancer